We are live on !
Find out more
Fagan Associates Portfolio holdings
AUM
$861M
Turnover
5.63%
1-Year Est. Return
31.91%
This Fund
S&P 500
This Quarter Est. Return
+1.4%
1 Year Est. Return
+31.91%
3 Year Est. Return
+126.69%
5 Year Est. Return
+149.41%
10 Year Est. Return
+595.96%
AUM
$156M
AUM Growth
+$4.81M
(+3.2%)
Cap. Flow
+$5.92M
Cap. Flow % of AUM
Cap. Flow %
3.8%
Top 10 Holdings %
Top 10 Hldgs %
34.74%
Holding
105
New
16
Increased
44
Reduced
31
Closed
10
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$3.39M |
| 2 |
AbbVie
ABBV
|
+$1.41M |
| 3 |
AT&T
T
|
+$1.25M |
| 4 |
Vanguard Total Bond Market
BND
|
+$1.25M |
| 5 |
HCA Healthcare
HCA
|
+$1.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delta Air Lines
DAL
|
+$1.52M |
| 2 |
D.R. Horton
DHI
|
+$1.43M |
| 3 |
Apple
AAPL
|
+$1.25M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$958K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 19.59% |
| 2 | Consumer Discretionary | 14.52% |
| 3 | Communication Services | 12.91% |
| 4 | Financials | 12.32% |
| 5 | Healthcare | 11.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$5.18T
| $6.45M | 4.14% |
269,688
-50,360
| -16% | -$1.25M |
2014 Q1
9 quarters
|
|
2
Nike
NKE
$56.4B
| $6.24M | 4.01% |
113,102
-5,098
| -4% | -$290K |
2014 Q1
9 quarters
|
|
3
State Street SPDR S&P Dividend ETF
SDY
$22.7B
| $6.08M | 3.91% |
72,440
+1,590
| +2% | +$129K |
2014 Q1
9 quarters
|
|
4
Meta Platforms (Facebook)
META
$1.64T
| $6.08M | 3.9% |
53,177
| – | – |
2014 Q1
9 quarters
|
|
5
Visa
V
$794B
| $5.08M | 3.26% |
68,464
-129
| -0.2% | -$10.1K |
2014 Q1
9 quarters
|
|
6
Mastercard
MA
$576B
| $5M | 3.21% |
56,815
-725
| -1% | -$69.2K |
2014 Q1
9 quarters
|
|
7
Starbucks
SBUX
$121B
| $4.92M | 3.16% |
86,050
+444
| +0.5% | +$25.2K |
2014 Q1
9 quarters
|
|
8
Lowe's Companies
LOW
$128B
| $4.87M | 3.13% |
61,504
-6,879
| -10% | -$532K |
2014 Q1
9 quarters
|
|
|
9
Vanguard Total Bond Market
BND
$165B
| $4.76M | 3.06% |
56,412
+15,021
| +36% | +$1.25M |
2014 Q4
6 quarters
|
|
10
Alphabet (Google) Class A
GOOGL
$3.64T
| $4.61M | 2.96% |
131,000
+3,600
| +3% | +$132K |
2015 Q4
2 quarters
|
|
11
GE Aerospace
GE
$344B
| $4.49M | 2.89% |
29,771
+201
| +0.7% | +$29.3K |
2014 Q1
9 quarters
|
|
12
JPMorgan Chase
JPM
$919B
| $4.34M | 2.79% |
69,780
+385
| +0.6% | +$24K |
2014 Q1
9 quarters
|
|
13
Microsoft
MSFT
$3.89T
| $4.28M | 2.75% |
83,641
+4,412
| +6% | +$229K |
2015 Q4
2 quarters
|
|
14
Vanguard Total International Bond ETF
BNDX
$84.7B
| $3.57M | 2.3% |
64,151
+12,317
| +24% | +$674K |
2014 Q3
7 quarters
|
|
15
Verizon
VZ
$192B
| $3.44M | 2.21% |
61,559
+330
| +0.5% | +$17.1K |
2014 Q1
9 quarters
|
|
|
16
Gilead Sciences
GILD
$208B
| $3.18M | 2.05% |
+38,165
| New | +$3.39M |
2016 Q2
0 quarters
|
|
|
CELG
17
DELISTED
Celgene Corp
CELG
| $3.11M | 2% |
31,510
+105
| +0.3% | +$10.9K |
2014 Q1
9 quarters
|
|
18
Bank of America
BAC
$352B
| $2.9M | 1.86% |
218,237
+421
| +0.2% | +$5.91K |
2014 Q1
9 quarters
|
|
19
Pfizer
PFE
$165B
| $2.75M | 1.77% |
82,322
+4,165
| +5% | +$133K |
2016 Q1
1 quarter
|
|
20
Cisco
CSCO
$377B
| $2.5M | 1.61% |
87,106
+5,849
| +7% | +$164K |
2014 Q2
8 quarters
|
|
|
TWX
21
DELISTED
Time Warner Inc
TWX
| $2.47M | 1.59% |
33,575
+350
| +1% | +$25.9K |
2015 Q4
2 quarters
|
|
22
Schwab US Broad Market ETF
SCHB
$44.2B
| $2.42M | 1.56% |
288,780
+22,572
| +8% | +$187K |
2014 Q1
9 quarters
|
|
23
Johnson & Johnson
JNJ
$688B
| $2.35M | 1.51% |
19,388
-293
| -1% | -$33.3K |
2014 Q1
9 quarters
|
|
24
iShares Preferred and Income Securities ETF
PFF
$11.4B
| $2.34M | 1.5% |
58,686
+7,523
| +15% | +$295K |
2014 Q4
6 quarters
|
|
25
ConocoPhillips
COP
$168B
| $2.3M | 1.48% |
52,768
-40
| -0.1% | -$1.76K |
2014 Q1
9 quarters
|
|
Similar funds
HP
LCM
Fagan Associates's Q2 2016 Portfolio in Review
As of Q2 2016, Fagan Associates held 105 positions worth $156M, up 3.2% from $151M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Fagan Associates deployed $5.92M of net new capital in Q2 2016, opening 16 new positions and adding to 44 existing holdings. Its largest new stake was Gilead Sciences: 38,165 shares worth $3.18M.
By sector, the portfolio is most concentrated in Miscellaneous at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was D.R. Horton, an estimated $1.43M trimmed.
- Fagan Associates's largest Q2 2016 buy was Gilead Sciences: 38,165 shares worth $3.18M.
- Fagan Associates added most to Vanguard Total Bond Market in Q2 2016, an estimated $1.25M increase.
- Fagan Associates's biggest Q2 2016 reduction was D.R. Horton, cutting an estimated $1.43M.
- Fagan Associates fully exited Delta Air Lines in Q2 2016, selling an estimated $1.52M.
- Fagan Associates's ten largest holdings make up 35% of its $156M portfolio in Q2 2016.
- Fagan Associates opened 16 new positions and closed 10 in Q2 2016.
- Fagan Associates's portfolio value rose 3.2% quarter-over-quarter to $156M.
Based on Fagan Associates's 13F filing for Q2 2016, filed 5 Aug 2016.